AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7813599
Drug: Roxindole 1
RxNorm normalized name: 3,3-Bis(4-hydroxyphenyl)oxindole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxindole 1 mg
Trial: 851140
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 10 per cent ethanol
Trial: 851140
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of ritodrine for 12 hours followed by oral ritodrine
Trial: 16946657
Drug: Bupivacaine and
RxNorm normalized name: bupivacaine and meloxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine and methylprednisolone (30 mL 0.25% bupivacaine and 40 mg methylprednisolone) before wound closure
Trial: 16946657
Drug: Bupivacaine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine alone (30 mL 0.25% bupivacaine) before closure
Trial: 16946657
Drug: Bupivacaine and
RxNorm normalized name: bupivacaine and meloxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine and methylprednisolone (30 mL 0.25% bupivacaine and 40 mg methylprednisolone) before incision
Trial: 16946657
Drug: Bupivacaine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine alone (30 mL 0.25% bupivacaine) before incision
Trial: 16946657
Drug: Control (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (30 mL 0.9% NaCl before wound closure)
Trial: 12880362
Drug: 1450-nm laser
RxNorm normalized name: aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1450-nm laser treatment with dynamic cooling
Trial: 10875487
Drug: Clarithromycin 200
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 200 mg twice daily for 8 weeks
Trial: 9180600
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg in one oral dose
Trial: 9180600
Drug: two oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two oral doses of 30 mg/kg at a 6-hr interval
Trial: 8257124
Drug: Ultramicrosize griseofulvin
RxNorm normalized name: Ultramicrosize Griseofulvin Tablets
DrugBank: Griseofulvin (DB00400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultramicrosize griseofulvin (UMSG) at 660 mg/day
Trial: 8257124
Drug: Ultramicrosize griseofulvin
RxNorm normalized name: Ultramicrosize Griseofulvin Tablets
DrugBank: Griseofulvin (DB00400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultramicrosize griseofulvin (UMSG) at 990 mg/day
Trial: 8257124
Drug: Itraconazole at
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole at 100 mg/day
Trial: 27614001
Drug: Mycophenolate treatment
RxNorm normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mycophenolate treatment
Trial: 23755093
Drug: Oxygen supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen supplementation at 2 or 3 L/min for 72 hours
Trial: 23755093
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (room air)
Trial: 15882228
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml erythrosine mouthwash for 15 s rinsing period
Trial: 15882228
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml erythrosine mouthwash for 30 s rinsing period
Trial: 15882228
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml erythrosine mouthwash for 60 s rinsing period
Trial: 15882228
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml erythrosine mouthwash for 90 s rinsing period
Trial: 10475181
Drug: Non-invasive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive treatment strategy
Trial: 8732321
Drug: Results of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Results of a self‐administered computerized assessment (PROQSY) of common mental disorders provided to the GP
Trial: 1890863
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow transplantation following high dose chemotherapy and radiation therapy (RT)
Trial: 1890863
Drug: RT followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT followed by adjuvant chemotherapy
Trial: 6579843
Drug: Budesonide (intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (intranasal corticosteroid)
Trial: 30556961
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% triamcinolone (TA) preparation
Trial: 30556961
Drug: Topical 0.2%
RxNorm normalized name: coal tar topical 0.2% topical soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.2% hyaluronic acid (HA) preparation
Trial: 27825036
Drug: S-MAPS (Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-MAPS (Standard MAPS treatment)
Trial: 25369831
Drug: Rimostil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimostil (50 mg)
Trial: 20371736
Drug: Linezolid and
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid and rifampin (combination)
Trial: 16937509
Drug: Routine non-operative
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine non-operative conservative treatments (group 2)
Trial: 14618331
Drug: Concurrent weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent weight training during FES cycle ergometry three times per week
Trial: 11737179
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hypotensive agent)
Trial: 3591681
Drug: Pindolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (mean dose 17 +/- 8 mg/day)
Trial: 3591681
Drug: Propranolol (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (130 +/- 40 mg/day)
Trial: 27442394
Drug: GA +
RxNorm normalized name: Sea-Omega + D Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GA + TAP-D block with 25 ml of 0.5% ropivacaine + 4 mg Dexamethasone
Trial: 27442394
Drug: GA +
RxNorm normalized name: Sea-Omega + D Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GA + TAP block with 25 ml of 0.5% ropivacaine
Trial: 15452808
Drug: Guided-tissue regeneration
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided-tissue regeneration therapy (GTR therapy)
Trial: 23204168
Drug: FMP2.1/AS02(A) malaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMP2.1/AS02(A) malaria vaccine
Trial: 19694381
Drug: Tamsulosin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.2 mg once a day)
Trial: 19694381
Drug: Tamsulosin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.2 mg once a day) + Tolterodine (2 mg twice a day)
Trial: 16476220
Drug: Long-term insulin
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term insulin treatment
Trial: 15470173
Drug: Desflurane 1
RxNorm normalized name: desflurane 1000 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desflurane 1 MAC, administered 30 min prior to the end of the surgical procedure.
Trial: 11304776
Drug: Epirubicin (110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (110 mg/m²) followed by paclitaxel (225 mg/m²) every 2 weeks for four cycles each, with granulocyte colony-stimulating factor support (Group A)
Trial: 11304776
Drug: Epirubicin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (80 mg/m²) followed by paclitaxel (175 mg/m²) every 3 weeks for six cycles (Group B)
Trial: 7506170
Drug: diclofenac (50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac (50mg twice daily)
Trial: 3318259
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + glipizide (3 X 10 mg/day)
Trial: 19047916
Drug: Prenatal drug
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal drug exposure (PDE) children remaining in maternal care
Trial: 19047916
Drug: Prenatal drug
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal drug exposure (PDE) children in nonmaternal care
Trial: 19047916
Drug: Community comparison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community comparison (CC) children
Trial: 14578832
Drug: High-dose midazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose midazolam (1 mg/kg, HDM)
Trial: 14578832
Drug: Standard-dose midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-dose midazolam (0.5 mg/kg, SDM)
Trial: 6570116
Drug: Cefoxitin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2 g) intravenously at the time of induction of anaesthesia
Trial: 6570116
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without the antibiotic
Trial: 30205746
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg BMS-986165 every other day
Trial: 30205746
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg BMS-986165 daily
Trial: 30205746
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg BMS-986165 twice daily
Trial: 30205746
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg BMS-986165 twice daily
Trial: 30205746
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg BMS-986165 daily
Trial: 27454263
Drug: Hydromorphone 0.25
RxNorm normalized name: HYDROMORPHONE 0.25MG/0.5ML INJ 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone 0.25 mg
Trial: 27454263
Drug: Ibuprofen 25
RxNorm normalized name: ibuprofen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 25 mg + Hydromorphone 0.125 mg
Trial: 27454263
Drug: Ibuprofen and
RxNorm normalized name: Ibuprofen and Famotidine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and Hydromorphone combination
Trial: 21194605
Drug: Levetiracetam 250
RxNorm normalized name: levetiracetam 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam 250 mg administered as an immediate-release tablet
Trial: 17497175
Drug: COMT Ex4‐76C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMT Ex4‐76C > G (Leu136Leu) polymorphism
Trial: 17497175
Drug: COMT haplotypes
RxNorm normalized name: levodopa, decarboxylase inhibitor and COMT inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMT haplotypes including variant allele for COMT Ex4‐76 C > G
Trial: 12118903
Drug: Darusentan 30
RxNorm normalized name: Darusentan
DrugBank: Darusentan (DB04883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darusentan 30 mg
Trial: 8201928
Drug: Norfloxacin 800
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norfloxacin 800 mg daily or Ciprofloxacin 1000 mg daily
Trial: 3493903
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose MTX (regimen I)
Trial: 3493903
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose MTX (regimen II)
Trial: 3493903
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (both regimens)
Trial: 27733165
Drug: ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen 400 mg PO and metoclopramide 10 mg PO
Trial: 27733165
Drug: tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tramadol 50 mg PO
Trial: 27733165
Drug: placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (two placebo pills)
Trial: 23558663
Drug: Radiographic assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiographic assessment of femoral implant position
Trial: 16729918
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) in addition to mebeverine hydrochloride
Trial: 10992533
Drug: Fluticasone aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone aqueous spray 200 microgram once daily (first season)
Trial: 10992533
Drug: Beclomethasone 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone 200 microgram twice daily (second season)
Trial: 8792038
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium 600 mg (24 mmol) daily for 12 weeks
Trial: 1377035
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (GpI)
Trial: 23399046
Drug: Machined implant
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machined implant neck design
Trial: 23399046
Drug: Anodized implant
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodized implant neck design
Trial: 22827973
Drug: Polyphenon E
RxNorm normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyphenon E (Poly E) 400 mg twice daily
Trial: 22827973
Drug: Polyphenon E
RxNorm normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyphenon E (Poly E) 600 mg twice daily
Trial: 22827973
Drug: Polyphenon E
RxNorm normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyphenon E (Poly E) 800 mg twice daily
Trial: 20845296
Drug: L‐carnitine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐carnitine 25 mg/day
Trial: 16200756
Drug: EMG-triggered robot-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMG-triggered robot-assisted therapy
Trial: 14571302
Drug: Ezetimibe (cholesterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (cholesterol absorption inhibitor)
Trial: 14571302
Drug: Ezetimibe in
RxNorm normalized name: Product containing ezetimibe in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe in combination with atorvastatin or simvastatin
Trial: 10770363
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (50 mg, 5 injections over 3 months)
Trial: 10770363
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 injections over 3 months)
Trial: 8901790
Drug: Diet containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet containing 300 g shrimp/d (590 mg dietary cholesterol/d)
Trial: 8901790
Drug: Diet containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet containing two large eggs per day (581 mg dietary cholesterol/d)
Trial: 2126147
Drug: Ranitidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (2 x 150 mg)
Trial: 1829300
Drug: Sucralfate (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (4 x 1 g)
Trial: 1829300
Drug: Indomethacin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (2 x 50 mg for 3 weeks)
Trial: 30739941
Drug: Subcostal TAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcostal TAP block with 10 mL of 0.25% bupivacaine
Trial: 30369310
Drug: Levosimendan (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (loading dose 12 μg/kg + 0.1 μg/kg per minute)
Trial: 30369310
Drug: Dobutamine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine (7.5 μg/kg per minute)
Trial: 21228025
Drug: subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous interferon beta-1a (44 mcg three times weekly)
Trial: 21228025
Drug: intramuscular interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular interferon beta-1a (30 mcg weekly)
Trial: 21228025
Drug: glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: glatiramer acetate (20 mg daily)
Trial: 20819471
Drug: Amoxicillin/clavulanate for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate for 2 weeks after ESS
Trial: 16428941
Drug: Metopimazine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metopimazine (7.5 mg x 2 t.i.d.)
Trial: 16428941
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg b.i.d.)
Trial: 29026170
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose AN-PEP
Trial: 29026170
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose AN-PEP
Trial: 21898717
Drug: Augmentation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation with buspirone
Trial: 11777630
Drug: Tailored chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored chemotherapy (FEC: cyclophosphamide, epirubicin, 5‐fluorouracil)
Trial: 11777630
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (CTCb: cyclophosphamide, thiotepa, carboplatin)
Trial: 10728155
Drug: Body weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body weight treatment
Trial: 10728155
Drug: Body fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body fat treatment (measured by anthropometrics)
Trial: 8083704
Drug: Weekly chemotherapy
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly chemotherapy (12 alternating cycles of ifosfamide/doxorubicin and cis-platin/etoposide)
Trial: 8083704
Drug: 3-week chemotherapy
RxNorm normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-week chemotherapy (6 alternating cycles of cyclophosphamide/doxorubicin/vincristine and PE)
Trial: 8083704
Drug: Weekly chemotherapy
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly chemotherapy
Trial: 8083704
Drug: 3-week chemotherapy
RxNorm normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-week chemotherapy
Trial: 2670465
Drug: Ciprofloxacin (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (IV 200 to 300 mg twice daily, followed by oral 500 mg twice daily)
Trial: 2670465
Drug: Ceftazidime (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (IV 1 to 2 g two to three times daily)
Trial: 59850
Drug: Bromocriptine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (mean daily dose 79 mg)
Trial: 25528557
Drug: Portrayals of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Portrayals of successfully treated schizophrenia, prescription painkiller addiction, and heroin addiction
Trial: 21477846
Drug: Activated partial
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated partial thromboplastin time‐adjusted UFH twice daily
Trial: 7956336
Drug: Tretinoin cream
RxNorm normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin cream (0.025 percent) applied daily for seven months
Trial: 3262546
Drug: miocamycin 50
RxNorm normalized name: Miocamycin
DrugBank: Miocamycin (DB13287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: miocamycin 50 mg/kg.day
Trial: 3262546
Drug: amoxycillin 60
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amoxycillin 60 mg/kg.day
Trial: 31317669
Drug: Calcium phosphate
RxNorm normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium phosphate (CaP)‐coated SLA surface implants
Trial: 31317669
Drug: Conventional SLA
RxNorm normalized name: slash pine pollen extract
DrugBank: Pinus elliottii pollen (DB10747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional SLA surface implants
Trial: 27690294
Drug: CIK cell
RxNorm normalized name: Testone CIK KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIK cell immunotherapy combined with standard TMZ chemoradiotherapy
Trial: 22834649
Drug: Transdermal 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 1% testosterone gel (5-7.5 mg/day)